A dozen years in the making, a UC Berkeley spinout nabs funds to take on the eye

Kyle LaHucik

Associate Editor

Largely funded by government grants for the better part of its first decade, a UC Berkeley spinout has secured a new CEO and the funds to take its research into the clinic in early 2024.

The biotech, named by one of the co-founder’s daughters and originally scrapped together with NIH funds in the aftermath of the 2008-09 financial crisis, is also on a mission to upend the treatment of wet age-related macular degeneration, or AMD, with an injectable drug that it claims could be more durable than the “800-pound gorilla” in the room, Genentech’s Lucentis and Regeneron/Bayer’s Eylea.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

TRENDING NOW

A dozen years in the making, a UC Berkeley spinout nabs funds to take on the eye

Kyle LaHucik

Associate Editor

To read Endpoints News become a free subscriber

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

A dozen years in the mak­ing, a UC Berke­ley spin­out nabs funds to take on the eye

Kyle LaHucik

Associate Editor

To read Endpoints News become a free subscriber

FDA sets De­cem­ber ap­proval de­ci­sion for first CRISPR ther­a­py, with 94% of pa­tients free of sick­le cell crises

As­traZeneca en­lists UK Treg biotech for type 1 di­a­betes, in­flam­ma­to­ry bow­el dis­ease deal fea­tur­ing $85M up­front

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

As­traZeneca flesh­es out piv­otal da­ta on $930M rare blood dis­or­der drug it wants to pair with Soliris, Ul­tomiris

Ed­i­tas gives first look at CRISPR da­ta in sick­le cell, be­ta tha­lassemia six months af­ter lay­offs, re­fo­cus

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

A dozen years in the making, a UC Berkeley spinout nabs funds to take on the eye

FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

AstraZeneca enlists UK Treg biotech for type 1 diabetes, inflammatory bowel disease deal featuring $85M upfront

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

AstraZeneca fleshes out pivotal data on $930M rare blood disorder drug it wants to pair with Soliris, Ultomiris

Editas gives first look at CRISPR data in sickle cell, beta thalassemia six months after layoffs, refocus

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape